Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate

A technology of insulin analogs and insulin-stimulating peptides, which is applied in the field of treating diabetes and reducing the side effects of pancreatic β cells in diabetic patients. It can solve the problems of increasing the half-life of physiologically active polypeptides, so as to improve the duration of efficacy in the body, enhance the duration and stability in the body effect on improving drug adherence

Pending Publication Date: 2017-04-05
HANMI PHARMA
View PDF15 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, such studies have focused on increasing the in vivo half-life of the physiologically active polypeptide, while aiming at reversing the adverse prognostic side effects of diabetes in patients that can reverse the decrease in pancreatic β-cell mass due to loss of pancreatic β-cell function and / or apoptosis Research on the method has not been completed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate
  • Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate
  • Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Embodiment 1: Preparation of single-chain insulin analog expression vector

[0134] To prepare insulin analogs, each with one amino acid change in the A or B chain, forward and reverse oligonucleotides (Table 2) were synthesized using available natural insulin expression vectors as templates, and performed PCR to amplify the individual analog genes.

[0135] The names of each amino acid sequence and each analog modified in the A chain or B chain are listed in Table 1 below. That is, analog 1 substitutes alanine for glycine at position 1 of the A chain, and analog 4 substitutes alanine for glycine at position 8 of the B chain.

[0136] Table 1

[0137] analog modified sequence Analog 1 A 1 G→A

Analog 2 A 2 I→A

Analog 3 A 19 Y→A

Analog 4 B 8 G→A

Analog 5 B 23 G→A

Analog 6 B 24 F→A

Analog 7 B 25 F→A

Analog 8 A 14 Y→E

Analog 9 A 14 Y→N

[0138] Primers use...

Embodiment 2

[0147] Example 2: Expression of Recombinant Insulin Analog Fusion Peptides

[0148] Recombinant insulin analogs were expressed under the control of the T7 promoter. E. coli BL21-DE3 (E. coli B F-dcm ompT hsdS(rB-mB-)gal DE3; Novagen) was transformed with the respective recombinant insulin analog expression vectors. Transformation was performed according to Novagen's recommended procedure. Single colonies transformed with individual recombinant expression vectors were inoculated in 2X Luria Broth (LB) medium containing ampicillin (50 / ml), and cultured at 37°C for 15 hours. Mix each culture solution of the recombinant strain with 2X LB medium containing 30% glycerol at a ratio of 1:1 (v / v), then aliquot 1 ml each into cryopreservation tubes, and store at -140°C . These samples were used as cell stocks for production of recombinant fusion proteins.

[0149] For the expression of recombinant insulin analogs, each 1 vial of cell stock was thawed, then inoculated in 500 ml of ...

Embodiment 3

[0150] Example 3: Recovery and refolding of recombinant insulin analogs

[0151] To convert the recombinant insulin analog expressed in Example 2 into a soluble form, the cells were disrupted and subsequently refolded. 100 g (wet weight) of the cell pellet was resuspended in 1 L of lysis buffer (50 mM Tris-HCl (pH 9.0), 1 mM EDTA (pH 8.0), 0.2M NaCl and 0.5% Triton X-100). Cells were disrupted at 15,000 psi operating pressure using a microfluidizer M-110EH (ACTechnology Corp. Model M1475C). The cell lysates thus disrupted were centrifuged at 7,000 rpm and 4°C for 20 minutes. The supernatant was discarded and the pellet was resuspended in 3 L of wash buffer (0.5% Triton X-100 and 50 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 1 mM EDTA). After centrifugation at 7,000 rpm and 4°C for 20 minutes, the cell pellet was resuspended in distilled water, followed by centrifugation in the same manner. The precipitate thus obtained was resuspended in 400 ml of buffer (1 M glycine, 3.78 g cyste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for preventing or treating diabetes and containing long-acting insulin analog and long-acting insulin secretion peptide conjugates, and a method for treating diabetes. More specifically, the composition can remarkably improve compliance by inhibiting weight gain caused by the administration of insulin, inhibiting emesis and nausea phenomena caused by the administration of an insulin secretion peptide and reducing the dose of insulin through the concomitant administration of the long-acting analog conjugate and the long-acting insulin secretion peptide conjugate. In addition, the present invention relates to: a pharmaceutical composition for alleviating the side effects of pancreatic beta cells in a patient with diabetes, and containing a long-acting insulin analog conjugate and a long-acting insulin secretion peptide conjugate; and a method for alleviating the side effects of pancreatic beta cells in a patient with diabetes. The method comprises a step of administering the composition. The composition, the pharmaceutical composition and the method are characterized in alleviation of side effects such as pancreatic beta cell dysfunction, pancreatic beta cell reduction, lipotoxicity and glucotoxicity, which are caused by the progression of diabetes.

Description

technical field [0001] The present invention relates to a composition comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate for preventing or treating diabetes, and a method for treating diabetes including the step of administering the composition. [0002] In addition, the present invention relates to a pharmaceutical composition comprising a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide conjugate for reducing side effects of pancreatic beta cells in diabetic patients, and to a pharmaceutical composition for reducing pancreatic β-cell side effects in diabetic patients. A method of beta cell side effects comprising the step of administering said composition. In particular, the present invention is characterized by reduced side effects such as pancreatic beta cell dysfunction, decreased pancreatic beta cell, and lipotoxicity or glucotoxicity associated with the progression of diabetes. Background techni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/28A61K38/26A61K47/54A61K47/56A61K47/62A61K47/68A61K47/30
CPCA61K38/26A61K47/30A61K47/60A61K47/50A61K47/6849A61K38/28A61P1/18A61P3/06A61P43/00A61P3/10A61K47/6811A61K2300/00C07K16/283
Inventor 金正国金大振许容豪崔仁荣郑圣烨权世昌
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com